Skip to main content
Premium Trial:

Request an Annual Quote

Medicare Coverage Set for Genomic Health's Oncotype Dx Colon Cancer Test

NEW YORK (GenomeWeb News) – Genomic Health today announced it has attained Medicare coverage for its Oncotype Dx colon cancer test.

Palmetto GBA, the designated national contractor for the test, has created a formal coverage policy for all Medicare recipients with stage II colon cancer. The policy is effective for all claims for services performed on or after Sept. 18, the Redwood City, Calif.-based genomics testing service firm said.

Palmetto made its decision based on two large QUASAR and Cancer and Leukemia Group B clinical validation studies and additional clinical utility information.

As of June 30, more than 10,000 doctors in more than 60 countries had ordered more than 200,000 Oncotype Dx colon cancer and breast cancer tests, Genomic Health said.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.